2017 American Transplant Congress
The Impact of the Donor Risk Index on Tumor Free Survival in Patients Undergoing Liver Transplantation with Hepatocellular Carcinoma.
In this study, we look at the impact of donor quality on tumor free survival in patients undergoing liver transplant (LT) with hepatocellular carcinoma (HCC)…2017 American Transplant Congress
Outcomes Following Transplantation for Hepatocellular Carcinoma.
Transplant, Recanati/Miller Transplantation Institute, New York, Ny
Objectives: To examine the prognostic features and outcomes of patients undergoing transplantation for hepatocellular carcinoma (HCC).Methods: A single-institution retrospective chart review was performed on all…2017 American Transplant Congress
Effect of Embolization History and Tumor Treatment Response on Plasma TGFβ in HCC Patients Listed for Liver Transplantation.
Purpose: TGFβ signaling is an integral pathway in hepatocellular carcinoma (HCC) metastasis. In this study, we monitored TGFβ levels and imaging response in HCC patients…2017 American Transplant Congress
Expanded Criteria for HCC in Liver Transplantation.
Introduction: Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the third highest cause of death related to malignancy. Since HCC diagnosis is…2017 American Transplant Congress
Hepatic Artery and Biliary Complications in Liver Transplant Recipients with Radioembolization Bridging Treatment for Hepatocellular Carcinoma.
Locoregional treatments are commonly applied in hepatocellular carcinoma (HCC) patients as a bridge to liver transplantation to prevent tumor progression during waiting time. We hypothesized…2017 American Transplant Congress
Blockade of Tim-3 and PD-1 Reverses Dysfunctions of Tumor Infiltrating Lymphocytes in HBV Related Hepatocellular Carcinoma.
The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
The immunosuppression of tumor infiltrating lymphocytes (TILs) is associated with rapid progress of hepatitis B virus related hepatocellular carcinoma (HBV-HCC). The inhibition molecules of T…2017 American Transplant Congress
Different Prognostic Factors for Early and Late Recurrence After Adult Living Donor Liver Transplantation for Hepatocellular Carcinoma.
Surgery, College of Medicine, Seoul National University, Seoul, Republic of Korea
Recurrence after liver transplantation (LT) for hepatocellular carcinoma (HCC) remains unsatisfactory. However, some patients with HCC recurrence after LT show good long-term survival results. The…2017 American Transplant Congress
Effects of the Gut-Liver Axis on Ischemia-Mediated Hepatocellular Carcinoma Recurrence in the Mouse Liver.
Background: There is growing evidence that liver graft ischemia-reperfusion (I/R) is a risk factor for hepatocellular carcinoma (HCC) recurrence after liver transplantation, but the involved…2017 American Transplant Congress
The Glasgow Prognostic Score and Its Variants Predict Mortality in Living Donor but Not in Deceased Donor Liver Transplantation for Hepatocellular Carcinoma: A Double-Center Validation Study.
The notion that inflammation parameters such as CRP and albumin might have an influence on outcome in malignant disease is gaining interest. Serum CRP- and…2017 American Transplant Congress
The Beneficial Effects of mTOR Inhibitors on Liver Resident Natural Killer Cells.
Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan
(Background) The immunosuppressive regimen currently used after organ transplantation reduces adaptive components. Therefore, the innate immune cells play pivotal roles in immune surveillance and defense…
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 23
- Next Page »